Last reviewed · How we verify
NCT05577442
Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer
Phase 2 trial testing Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy in Breast Neoplasm Female in 52 participants. Status unknown.
20 October 2023
Quick facts
| Lead sponsor | Peking University Cancer Hospital & Institute |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 52 |
| Start date | 20 October 2022 |
| Primary completion | 20 October 2023 |
| Estimated completion | 20 October 2024 |
Drugs / interventions tested
- Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy — full drug profile →
Conditions studied
- Breast Neoplasm Female — all drugs for Breast Neoplasm Female →
Sponsor
Peking University Cancer Hospital & Institute
Who can join
Adults 18 to 75, female only, with Breast Neoplasm Female. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study investigates the efficacy and safety of trastuzumab, pyrotinib combined with dalpiciclib and endocrine therapy for patients with advanced HR+/HER2+ brest cancer, providing more possible effective regimens for the survival benefit of these patients in clinical practice.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Novel HER-2 Targeted Therapies in Breast Cancer.
Fernandes CL, Silva DJ, Mesquita A. · · 2023 · cited 9× · PMID 38201515 · DOI 10.3390/cancers16010087 -
Endocrine therapy plus HER2-targeted therapy, another favorable option for HR+/HER2+ advanced breast cancer patients.
Liang Y, Liu X, Yun Z, Li K, et al · · 2024 · PMID 38188468 · DOI 10.1177/17588359231220501
Verify or expand the search:
- PubMed search for NCT05577442
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Neoplasm Female
Currently open trials in the same condition.
- NCT07465523 — A Novel Approach in the Evaluation of Breast Masses With Doppler US · recruiting
- NCT06711523 — Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy · Phase 3 · active not recruiting
- NCT05277935 — Wearable Enhanced Fitness Tracking for Metastatic Breast Cancer Patients Using Endocrine Treatment and Palbociclib · NA · recruiting
- NCT06234137 — A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrot · NA · recruiting
- NCT04812652 — Digitally Distributed Yoga for Women Treated for Breast Cancer · NA · active not recruiting
Other Peking University Cancer Hospital & Institute trials
Trials by the same sponsor.
- NCT07527806 — Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Im · Phase 2 · not yet recruiting
- NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
- NCT07417241 — SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study · Phase 2 · not yet recruiting
- NCT07470203 — Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer · not yet recruiting
- NCT07394192 — Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-I · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05577442 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University Cancer Hospital & Institute
- Last refreshed: 19 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05577442.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing